Align Technology (ALGN) to Release Earnings on Wednesday

Align Technology (NASDAQ:ALGN) is expected to issue its Q1 2026 results after the market closes on Wednesday, April 29th. Analysts expect Align Technology to post earnings of $2.26 per share and revenue of $1.0215 billion for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:30 PM ET.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $3.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.99 by $0.30. Align Technology had a net margin of 10.17% and a return on equity of 15.16%. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter last year, the firm earned $2.44 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts expect Align Technology to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Align Technology Price Performance

Shares of Align Technology stock opened at $189.61 on Monday. The stock has a market cap of $13.58 billion, a price-to-earnings ratio of 33.50, a P/E/G ratio of 2.06 and a beta of 1.81. Align Technology has a twelve month low of $122.00 and a twelve month high of $208.30. The company’s fifty day moving average is $179.78 and its 200 day moving average is $163.08.

Analyst Upgrades and Downgrades

A number of research firms have commented on ALGN. Mizuho upped their price target on Align Technology from $200.00 to $215.00 and gave the company an “outperform” rating in a research report on Thursday, February 5th. Robert W. Baird set a $218.00 price objective on Align Technology in a research report on Thursday, February 5th. Wells Fargo & Company lifted their price objective on Align Technology from $181.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Piper Sandler boosted their price target on shares of Align Technology from $220.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 21st. Finally, Wall Street Zen raised shares of Align Technology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Eight analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Align Technology currently has an average rating of “Moderate Buy” and a consensus target price of $203.92.

Insider Activity

In related news, EVP John Morici sold 7,969 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $189.31, for a total transaction of $1,508,611.39. Following the transaction, the executive vice president directly owned 8,237 shares of the company’s stock, valued at $1,559,346.47. This represents a 49.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.75% of the stock is owned by insiders.

Hedge Funds Weigh In On Align Technology

Several institutional investors have recently made changes to their positions in the stock. Invesco Ltd. grew its stake in shares of Align Technology by 37.4% in the 3rd quarter. Invesco Ltd. now owns 1,497,535 shares of the medical equipment provider’s stock valued at $187,521,000 after buying an additional 407,559 shares during the period. Bank of America Corp DE lifted its stake in shares of Align Technology by 72.0% in the third quarter. Bank of America Corp DE now owns 1,353,125 shares of the medical equipment provider’s stock valued at $169,438,000 after buying an additional 566,488 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Align Technology by 65.8% during the fourth quarter. AQR Capital Management LLC now owns 1,196,428 shares of the medical equipment provider’s stock valued at $186,822,000 after buying an additional 474,756 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Align Technology by 30.9% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,005,837 shares of the medical equipment provider’s stock worth $157,061,000 after acquiring an additional 237,581 shares in the last quarter. Finally, Morgan Stanley raised its holdings in shares of Align Technology by 4.7% in the 4th quarter. Morgan Stanley now owns 944,850 shares of the medical equipment provider’s stock worth $147,539,000 after acquiring an additional 42,282 shares during the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

Align Technology Company Profile

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.